Iratumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Iratumumab
Accession Number
DB05550
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MDX 060 / MDX-060
Categories
UNII
AYH22O1B1U
CAS number
640735-09-7

Pharmacology

Indication

Investigated for use/treatment in lymphoma (unspecified).

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Iratumumab.
AbituzumabThe risk or severity of adverse effects can be increased when Iratumumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Iratumumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Iratumumab.
AducanumabThe risk or severity of adverse effects can be increased when Iratumumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Iratumumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Iratumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Iratumumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Iratumumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Iratumumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Iratumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD)1
2WithdrawnTreatmentLymphoma, Large-Cell1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:25 / Updated on November 02, 2018 06:11